Loading clinical trials...

Determination of Walking, Balance, Fall Risk and Kinesiophobia in Individulas with Alzheimer's Dementation | Clinical Trials | Clareo Health

COMPLETED

Determination of Walking, Balance, Fall Risk and Kinesiophobia in Individulas with Alzheimer's Dementation

NCT05201768•Kırıkkale University

View on ClinicalTrials.gov

Summary

THE OBJECTIVE OF THE RESEARCHERS IS TO DETERMINE WALKING, BALANCE, FALL RISK AND KINESIOPHOBIA IN INDIVIDUALS WITH ALZHEIMER'S DEMENTATION.

Detailed Description

The gait, balance, fall risks and kinesiophobia of individuals with Alzheimer's Dementia will be evaluated and compared with healthy individuals.

Eligibility

Age

50 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•INDEPENDENT walker diagnosed with Alzheimer's Dementia

Exclusion Criteria

•Having a disability to do physical activity Those who have had an operation in the last 6 months

Locations (1)

Kırıkkale University

Kırıkkale, Turkey (Türkiye)

Key Dates

Start Date

March 1, 2022

Primary Completion Date

June 1, 2022

Completion Date

November 1, 2022

Last Updated

December 3, 2024

Enrollment

ACTUAL participants

Conditions

Alzheimer Disease

Interventions

balance tests,questionnaire

OTHER

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

NCT07178210

Alzheimer DiseaseLymphatic Obstruction

View study

RECRUITINGEARLY_PHASE1

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314

Depressive SymptomsDepression+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 3, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Determination of Walking, Balance, Fall Risk and Kinesiophobia in Individulas with Alzheimer's Dementation

Inclusion Criteria

Exclusion Criteria

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

Longitudinal Early-onset Alzheimer's Disease Study Protocol

A Study of AMDX-2011P in Participants With Alzheimer's Disease